THE Department of Health stated that the number of detected Covid-19 cases countrywide continued to decline since mid-August.
Mzansi has seen under 3 000 cases a day with the recovery rate reaching almost 90% in the recent week.
But while the country seems to be controlling transmissions, Wits University announced that they have resumed with their Oxford Covid-19 (Ox1nCov19) vaccine trial.
This week, the South African Health Products Regulatory Authority and local ethics committees approved resuming the vaccination in the country.
According to Wits Senior Communications Officer Deborah Minors, the vaccination in the Ox1nCov19 vaccine trial in the UK paused last week following a medical event in one trial participant in the UK.
She said the spokesperson for the University of Oxford said the UK’s independent review process had concluded and following the recommendations of both the independent safety review committee and the UK’s Medicines and Healthcare products Regulatory Agency, the trials will recommence in the UK.
Executive Director of the Vaccines and Infectious Diseases Analytics Research Unit (VIDA), Professor Shabir Madh who leads the Ox1nCov19 trial in South Africa, confirmed yesterday (Wednesday) that vaccination resumed in South Africa on Tuesday.
“The South African study is overseen by the same independent Data and Safety Monitoring Committee as in the UK, so all sites in South Africa paused vaccination. “The South African Health Products Regulatory Authority and Wits University ethics committees have now approved resuming vaccination and we have done so,” said Madhi.
He said globally some 18 000 individuals have received study vaccines as part of this trial.
He also added that trials such as this it was expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.